Candida auris Inpatient Screening in Collaboration with the Public Health Department

Christian Greco; Heather Smith; Brandy Gilbert; Jennifer Martin; Justin Smyer; Michael Haden; Christina Liscynesky; Shandra R Day; Nora Colburn

doi:10.1016/j.ajic.2024.05.010

Candida auris Inpatient Screening in Collaboration with the Public Health Department

Am J Infect Control. 2024 May 16:S0196-6553(24)00502-9. doi: 10.1016/j.ajic.2024.05.010. Online ahead of print.

Authors

Christian Greco¹, Heather Smith², Brandy Gilbert³, Jennifer Martin², Justin Smyer², Michael Haden⁴, Christina Liscynesky¹, Shandra R Day¹, Nora Colburn⁵

Affiliations

¹ Department of Internal Medicine, Division of Infectious Diseases, The Ohio State University Wexner Medical Center.
² Department of Clinical Epidemiology, The Ohio State University Wexner Medical Center.
³ Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, The Ohio State University Wexner Medical Center.
⁴ Department of Internal Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus.
⁵ Department of Internal Medicine, Division of Infectious Diseases, The Ohio State University Wexner Medical Center. Electronic address: nora.colburn@osumc.edu.

PMID: 38761851
DOI: 10.1016/j.ajic.2024.05.010

Abstract

Candida auris is a multidrug resistant (MDR) fungal pathogen that is associated with nosocomial outbreaks in patients with extensive healthcare exposure and treatment outside of the US. The Ohio Department of Health recommends C. auris screening in high risk patients. However, this can be operationally difficult for many healthcare facilities. This report describes a C. auris and Carbapenem-resistant Enterobacterales (CRE) inpatient screening program done in collaboration with state public health.

Keywords: Candida auris; public health; screening; surveillance.